Fungal Infections in Transplant and Oncology Patients

Hematology/Oncology Clinics of North America

Volumn 25, Issue 1, 2011, Pages 193-213

  Person, Anna K ^a   Kontoyiannis, Dimitrios P ^b   Alexander, Barbara D ^c  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fungus; Hematopoietic stem cell transplant; Invasive fungal infection; Oncology; Solid organ transplant; Transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ATOVAQUONE; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; HLA ANTIGEN; ITRACONAZOLE; MICAFUNGIN; PENTAMIDINE; PLACEBO; POSACONAZOLE; PREDNISONE; PYRROLE; RAPAMYCIN; RAVUCONAZOLE; TACROLIMUS; VORICONAZOLE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGING; APLASTIC ANEMIA; BLASTOMYCOSIS; COCCIDIOIDOMYCOSIS; CONIDIUM; CORD BLOOD STEM CELL TRANSPLANTATION; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIABETES MELLITUS; DONOR SELECTION; DRUG DOSE REDUCTION; DYSPNEA; FEVER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPTYSIS; HISTOPLASMOSIS; HLA MATCHING; HUMAN; HYPOTHERMIA; INTERSTITIAL PNEUMONIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; IRON OVERLOAD; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY FAILURE; REVIEW; SYSTEMIC MYCOSIS; THORAX PAIN; TRACHEOBRONCHITIS; VISUAL DISORDER; VOMITING; ZYGOMYCOSIS;

EID: 78651073898     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.11.013     Document Type: Review

References (128)

1. Martino R., Subira M., Rovira M., et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002, 116(2):475-482.
2. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102(3):827-833.
3. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000, 31(2):545-553.
4. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9):1172-1177.
5. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7):909-917.
6. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38(9):1237-1242.
7. Husain S., Munoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005, 40(1):89-99.
8. Pugliese F., Ruberto F., Cappannoli A., et al. Incidence of fungal infections in a solid organ recipients dedicated intensive care unit. Transplant Proc 2007, 39(6):2005-2007.
9. Grossi P., Farina C., Fiocchi R., et al. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000, 70(1):112-116.
10. DiNubile M.J., Hille D., Sable C.A., et al. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005, 50(5):443-449.
11. Bodey G., Bueltmann B., Duguid W., et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992, 11(2):99-109.
12. Chamilos G., Luna M., Lewis R.E., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91(7):986-989.
13. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999, 12(2):323-326.
14. Lass-Florl C., Kofler G., Kropshofer G., et al. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998, 42:497-502.
15. Steinbach W.J., Perfect J.R., Schell W.A., et al. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrobial Agents Chemother 2004, 48(9):3217-3225.
16. Munoz P., Rodriguez C., Bouza E., et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004, 4(4):636-643.
17. Husain S., Alexander B.D., Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37(2):221-229.
18. Minari A., Husni R., Avery R.K., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002, 4(4):195-200.
19. Marr K.A., Patterson T., Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002, 16(4):878-883.
20. Mehrad B., Paciocco G., Martinez F.J., et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001, 119(1):169-175.
21. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33(11):1824-1833.
22. Pasqualotto A.C., Rosa D.D., Medeiros L.R., et al. Candidaemia and cancer: patients are not all the same. BMC Infect Dis 2006, 6:50.
23. Sipsas N.V., Lewis R.E., Tarrand J., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009.
24. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326(13):845-851.
25. Marr K.A., Seidel K., White T.C., et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181(1):309-316.
26. Van Burik J.H., Leisenring W., Myerson D., et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine 1998, 77:246-254.
27. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20(1):115-125.
28. Horn D.L., Neofytos D., Anaissie E.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48(12):1695-1703.
29. Palmer S.M., Perfect J.R., Howell D.N., et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998, 17(10):1029-1033.
30. Fraser V.J., Jones M., Dunkel J., et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992, 15(3):414-421.
31. Alexander B.D., Schell W.A. Hyalohyphomycosis. Atlas of fungal infections 2006, 253-266. Current Medicine Group, Inc, Philadelphia. 2nd edition. C.A. Kauffman, G.L. Mandell (Eds.).
32. Schell W.A. New aspects of emerging fungal pathogens. A multifaceted challenge. Clin Lab Med 1995, 15(2):365-387.
33. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41(5):634-653.
34. Kontoyiannis D.P., Wessel V.C., Bodey G.P., et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30(6):851-856.
35. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39(7):425-429.
36. Marty F.M., Cosimi L.A., Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350(9):950-952.
37. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39(4):584-587.
38. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39(5):743-746.
39. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191(8):1350-1360.
40. Sepkowitz K.A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002, 34(8):1098-1107.
41. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004, 4(Suppl 10):135-141.
42. De Castro N., Neuville S., Sarfati C., et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005, 36(10):879-883.
43. Torres H.A., Chemaly R.F., Storey R., et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006, 25(6):382-388.
44. Kovacs J.A., Halpern J.L., Swan J.C., et al. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol 1988, 140(6):2023-2031.
45. Meuwissen J.H., Tauber I., Leeuwenberg A.D., et al. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis 1977, 136(1):43-49.
46. Stringer J.R. Pneumocystis. Int J Med Microbiol 2002, 292(5-6):391-404.
47. Dummer J.S., Montero C.G., Griffith B.P., et al. Infections in heart-lung transplant recipients. Transplantation 1986, 41(6):725-729.
48. Gryzan S., Paradis I.L., Zeevi A., et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am Rev Respir Dis 1988, 137(6):1268-1274.
49. Neff R.T., Jindal R.M., Yoo D.Y., et al. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009, 88(1):135-141.
50. MacDougall L., Kidd S.E., Galanis E., et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007, 13(1):42-50.
51. Chayakulkeeree M., Perfect J.R. Cryptococcosis. Infect Dis Clin North Am 2006, 20(3):507-544. v-vi.
52. Mirza S.A., Phelan M., Rimland D., et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36(6):789-794.
53. Pappas P.G., Perfect J.R., Cloud G.A., et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33(5):690-699.
54. Baddley J.W., Stroud T.P., Salzman D., et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32(9):1319-1324.
55. Vilchez R., Shapiro R., McCurry K., et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003, 16(5):336-340.
56. Kauffman C.A. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006, 20(3):645-662. vii.
57. Wheat L.J., Slama T.G., Norton J.A., et al. Risk factors for disseminated or fatal histoplasmosis. Analysis of a large urban outbreak. Ann Intern Med 1982, 96(2):159-163.
58. Peddi V.R., Hariharan S., First M.R. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant 1996, 10(2):160-165.
59. Freifeld A.G., Iwen P.C., Lesiak B.L., et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005, 7(3-4):109-115.
60. Limaye A.P., Connolly P.A., Sagar M., et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 2000, 343(16):1163-1166.
61. Serody J.S., Mill M.R., Detterbeck F.C., et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993, 16(1):54-58.
62. Bradsher R.W., Chapman S.W., Pappas P.G. Blastomycosis. Infect Dis Clin North Am 2003, 17(1):21-40. vii.
63. Gauthier G.M., Safdar N., Klein B.S., et al. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 2007, 9(4):310-317.
64. Glenn T.J., Blair J.E., Adams R.H. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol 2005, 43(8):705-710.
65. Blair J.E., Logan J.L. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001, 33(9):1536-1544.
66. Wright P.W., Pappagianis D., Wilson M., et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003, 37(9):1265-1269.
67. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48(3):265-273.
68. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100(13):4358-4366.
69. Upton A., Kirby K.A., Carpenter P., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44(4):531-540.
70. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338(24):1741-1751.
71. Patel R. Infections in recipients of kidney transplants. Infect Dis Clin North Am 2001, 15(3):901-952. xi.
72. van Hal S.J., Marriott D.J., Chen S.C., et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis 2009, 11(2):122-127.
73. Singh N., Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003, 22(3):258-266.
74. Sole A., Morant P., Salavert M., et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005, 11(5):359-365.
75. Fungal infections. Am J Transplant 2004, 4(Suppl 10):110-134.
76. Husain S., Zaldonis D., Kusne S., et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006, 8(4):213-218.
77. Singh N., Limaye A.P., Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006, 44(5):445-449.
78. Zaas A.K., Alexander B.D. Prevention of fungal infections in lung transplant patients. Current Fungal Infection Reports 2008, 2:103-111.
79. Garcia-Vidal C., Upton A., Kirby K.A., et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47(8):1041-1050.
80. Miceli M.H., Dong L., Grazziutti M.L., et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006, 37(9):857-864.
81. Maertens J., Demuynck H., Verbeken E.K., et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999, 24(3):307-312.
82. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359(17):1766-1777.
83. Zaas A.K. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008, 4(6):e1000101.
84. Issa N.C., Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009, 48(6):772-786.
85. Gabardi S., Kubiak D.W., Chandraker A.K., et al. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int 2007, 20(12):993-1015.
86. Iversen M., Burton C.M., Vand S., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007, 26(12):879-886.
87. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003, 17(1):113-134. viii.
88. Benedetti E., Gruessner A.C., Troppmann C., et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996, 183(4):307-316.
89. George M.J., Snydman D.R., Werner B.G., et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997, 103(2):106-113.
90. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002, 35(4):359-366.
91. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
92. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360.
93. VFend. Package insert 2008, Pfizer Inc, New York.
94. Weiss J., Ten Hoevel M.M., Burhenne J., et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009, 49(2):196-204.
95. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34(5):563-571.
96. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44(1):2-12.
97. Alexander B.D., Perfect J.R., Daly J.S., et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008, 86(6):791-796.
98. Pfaller M.A., Messer S.A., Boyken L., et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008, 46(8):2568-2572.
99. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrobial Agents Chemother 2008, 52(7):2468-2472.
100. Maertens J., Glasmacher A., Herbrecht R., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107(12):2888-2897.
101. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53(5):337-349.
102. Steinbach W.J., Stevens D.A., Denning D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003, 37(Suppl 3):S188-S224.
103. Caillot D., Thiebaut A., Herbrecht R., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110(12):2740-2746.
104. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81(3):320-326.
105. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
106. Spellberg B., Walsh T.J., Kontoyiannis D.P., et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009, 48(12):1743-1751.
107. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47(4):503-509.
108. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42(7):e61-e65.
109. Almyroudis N.G., Sutton D.A., Fothergill A.W., et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrobial Agents Chemother 2007, 51(7):2587-2590.
110. Lamaris G.A., Lewis R.E., Chamilos G., et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008, 198(2):186-192.
111. Perkhofer S., Locher M., Cuenca-Estrella M., et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrobial Agents Chemother 2008, 52(7):2636-2638.
112. Reed C., Bryant R., Ibrahim A.S., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47(3):364-371.
113. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36(9):1122-1131.
114. Kovacs J.A., Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009, 301(24):2578-2585.
115. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000, 30(4):710-718.
116. Singh N., Alexander B.D., Lortholary O., et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007, 195(5):756-764.
117. Dromer F., Mathoulin-Pelissier S., Launay O., et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007, 4(2):e21.
118. Singh N., Lortholary O., Alexander B.D., et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005, 40(12):1756-1761.
119. Dignani M.C., Anaissie E.J., Hester J.P., et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11(10):1621-1630.
120. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13(2):236-301.
121. Lee F.Y., Mossad S.B., Adal K.A. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999, 159(12):1301-1309.
122. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331(20):1325-1330.
123. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36(10):1221-1228.
124. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366(9495):1435-1442.
125. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347(25):2020-2029.
126. Kuse E.R., Chetchotisakd P., da Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369(9572):1519-1527.
127. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356(24):2472-2482.
128. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45(7):883-893.